BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BASF Pharma Ingredients and Services

The innovative PeroXeal™ packaging concept sets new standards in the market by protecting BASF’s PVP-based excipients (marketed under the trade name Kollidon®) from environmental influences such as atmospheric oxygen. Thanks to the new packaging, which applies established barrier technologies to the needs of the pharmaceutical ingredient market, Kollidon’s peroxide content can be reduced to a level comparable with that of naturally-based raw materials. This significantly increases stability and ensures consistent performance – and makes Kollidon a viable alternative to cellulose when working with oxygen-sensitive ingredients.

As the packaging extends Kollidon’s retest period to up to four years, customers benefit from increased flexibility in the planning, handling and shipping of goods. Additionally, the longer shelf life helps mitigate risk and provides a greater safety margin.

The PeroXeal packaging concept is a combination of multiple film layers complemented by inert gas flushing and heat sealing. The foil comprises three distinct functional layers, each specifically designed to shield the product from environmental influences. The transparent inner lining is compatible with non-invasive NIR testing – so packaging remains airtight until the product is put to use.

A large number of Kollidon products are already available in PeroXeal packaging – at no additional cost to the customer.

Contact details

www.kollidon.com/kollidon/PeroXealconcept.aspx?
pharma-ingredients@basf.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
18%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search

Click here